Alexion broadens pipeline with $855M Wilson Therapeutics buy

The deal hands Alexion WTX101, a candidate in Phase 3 testing for a rare genetic condition called Wilson's disease.

By Jacob Bell • April 11, 2018

Novartis buys AveXis for $8.7B, broadening gene therapy bet

Acquiring the U.S. biotech and its late-stage candidate for spinal muscular atrophy is new CEO Vas Narasimhan's first major deal as Novartis chief.

By Ned Pagliarulo • April 9, 2018

Ferring picks up microbiome specialist Rebiotix

The Swiss pharma brings in a microbial approach to C diff. infections by buying a microbiome pipeline.

By Suzanne Elvidge • April 6, 2018

Autolus pairs up with Miltenyi to manufacture T-cell therapies

Autolus aims to automate its cell processing steps utilizing Miltenyi tools, which could in theory make the complex manufacturing process more reproducible.

By Randi Hernandez • April 5, 2018

Boehringer joins checkpoint inhibitor race with OSE deal

In a heavily back-ended agreement, Boehringer is betting on a second wave of I/O drug development through the exploration of targets other than PD-1/L1.

By Ned Pagliarulo • April 5, 2018

Novo charts course for sickle cell amid headwinds in hemophilia

The Danish drugmaker lined up $400 million for access to a young biotech's investigational therapy.

By Jacob Bell • April 5, 2018

Lilly's next diabetes play would have patients implanted with engineered stem cells

In addition to an equity investment and $63 million upfront, Lilly's latest deal dangles $410 million in milestones to Sigilon Therapeutics.

By Jacob Bell • April 4, 2018

Pfizer inks deal handing CAR-T assets to newly launched biotech

The new biotech, which will be 25% owned by Pfizer, will be headed by former Kite execs looking to find success in developing allogeneic CAR-T therapy.

By Randi Hernandez • April 3, 2018

Walmart reportedly in early talks to acquire Humana

The companies already partner on Medicare Part D drug plans. But a deal could boost Humana's group market offerings to compete with other insurers, suggests one analyst.

By David Lim • April 2, 2018

Eisai partners with Nichi-Iko in generics pact

Under the deal, Eisai will transfer ownership of its generics unit to Nichi-Iko, supplying its new partner with API from a manufacturing plant in India.

By Ned Pagliarulo • March 29, 2018

Celgene, bluebird revise deal to co-develop CAR-T therapy

The market doesn't seem impressed by the updated agreement between the companies.

By Suzanne Elvidge • March 29, 2018

Takeda eyes Shire takeover

The Japanese pharma has until April 25 to announce whether it intends to submit a formal offer for the Irish specialty pharma.

By Jacob Bell • March 28, 2018

GSK buys Novartis stake in consumer business for $13B

Days after dropping its bid for Pfizer's consumer unit, GSK solidified full ownership of a joint venture set up in an asset swap with Novartis.

By Ned Pagliarulo • March 27, 2018

Prescribed Reading: AbbVie disappoints; Regeneron deals in genes

Investors questioned AbbVie's strategy in oncology after a clinical miss. Elsewhere, Regeneron partnered with Alnylam to probe the potential of a genetic discovery.

By Lisa LaMotta • March 23, 2018

Regeneron, Alnylam partner to turn discovery into new drugs for NASH

Scientists at Regeneron's labs found a genetic variant linked to lower risk of liver disease — a target that could be ideally suited for Alnylam's RNAi tech.

By Ned Pagliarulo • March 22, 2018

SemaThera inks deal for China and Japan

A diabetes eye drug deal pushes SemaThera towards the Asian market and provides financing for clinical trials. 

By Suzanne Elvidge • March 22, 2018

Celgene picks up early neuro drugs in Prothena deal

A $150 million upfront payment gives Celgene access to three candidates, boosting its presence in Alzheimer's and other neurodegenerative diseases.

By Lisa LaMotta • March 21, 2018

Mundipharma inks third biosimilar deal with Celltrion

The European conglomerate will commercialize the South Korean company's copycat version of Herceptin.

By Lisa LaMotta • March 20, 2018

Novartis taps Harvard tech to advance cancer immunotherapy efforts

Outside of cell therapy, Novartis trails in immuno-oncology. But, as its deal with Harvard shows, it aims to lead in developing second-generation approaches. 

By Randi Hernandez • March 20, 2018

J&J to sell Lifescan, dropping out of diabetes diagnostics

The pharma giant intends to divest its Lifescan unit to a private investment firm for $2.1 billion.

By Suzanne Elvidge • March 19, 2018

Lundbeck bulks up neuro pipeline with Prexton buy

As part of the deal, Lundbeck will add a first-in-class small-molecule compound, foliglurax, to its growing CNS repertoire.

By Randi Hernandez • March 16, 2018

Prescribed Reading: Neuro's comeback tour

Activity in the neuroscience space spiked higher, with a flurry of licensing deals highlighting BioPharma Dive's prediction the field is ready for a resurgence.

By Lisa LaMotta • March 16, 2018

Biohaven bullish on CGRP market with new Bristol-Myers terms

Rather than pay excessive royalties later, Biohaven will hand over a $50 million upfront payment financed by a private placement.

By Randi Hernandez • March 13, 2018

WuXi Biologics, Adagene ally to address hard-to-manufacture antibodies

Conventional approaches to make drug product for antibody-based medicines is not always sufficient — a challenge the companies seek to address.

By Randi Hernandez • March 9, 2018

CytomX loses out on $264M as Pfizer exits deal

Years of Probody Drug Conjugate research hadn't led to any clinical-stage programs, pushing the big pharma to cut ties with CytomX.

By Jacob Bell • March 9, 2018